The global Animal Antibacterial and Antibiotics Market is projected to grow from approximately USD 4.9 billion in 2024 to ...

Investigators compared outcomes between patients with stage II/III colon cancer given adjuvant aspirin and those given ...

Bayer is thought to be closest behind Merck with eliapixant, reporting encouraging results in the phase 2b PAGANINI trial last September, which used the same efficacy endpoint as Merck's studies.

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

The decision comes just a few months after Bayer reported encouraging results for eliapixant in chronic cough – the same indication sought by Merck for gefapixant – saying it hit its objective ...

Getting more effective drugs for patients in need as quickly as possible should be the ultimate reward and objective.

With a market capitalization of just $1.9 billion, Recursion still provides a potentially good entry point for investors, but ...

Arcus Biosciences develops late-stage immunotherapies, with Domvanalimab and Casdatifan leading the way. See why I rate RCUS ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Two new papers by a team of researchers at Boston University, the Indiana University School of Medicine and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and the German Center for ...